Kazia Therapeutics (Kazia Therapeutics) Interest Expense : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kazia Therapeutics's interest expense for the six months ended in Jun. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kazia Therapeutics's Operating Income for the six months ended in Jun. 2023 was $ -7.05 Mil. Kazia Therapeutics's Interest Expense for the six months ended in Jun. 2023 was $ 0.00 Mil. Kazia Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Kazia Therapeutics Interest Expense Historical Data

The historical data trend for Kazia Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Interest Expense Chart

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Kazia Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Kazia Therapeutics (NAS:KZIA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kazia Therapeutics's Interest Expense for the six months ended in Jun. 2023 was $0.00 Mil. Its Operating Income for the six months ended in Jun. 2023 was $-7.05 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was $0.00 Mil.

Kazia Therapeutics's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Kazia Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Kazia Therapeutics Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204